-
Chairman Shi Yuanyuan attended the third meeting of the Advisory Committee and Policy Advisory Committee of Pingshan ICH ParkOn December 12, Shi Yuanyuan, chairman of our company, attended the "Third Meeting of Pingshan ICH Park Advisory Committee and Policy Advisory Committe...01-15 -
Shenzhen Cell Valley wholly-owned subsidiary Junhou biological innovation research team project launch meeting was successfully heldRecently, Guangdong Junhou Biomedicine Co., LTD., a wholly-owned subsidiary of Shenzhen Cell Valley, won the ninth batch of innovative scientific research team ...01-15 -
Guangdong Junhou Biomedicine Co., Ltd. won the ISO9001 quality management system certificationOn October 27, 2022, Guangdong Junhou Biopharmaceutical Co., LTD., a wholly-owned subsidiary of Shenzhen Cell Valley Biopharmaceutical Co., LTD. (hereinafte...01-15 -
Shi Yuanyuan was invited to attend the closed-door meeting of industry leaders at the 2022 Shenzhen International Biomedical Industry Innovation and Development ConferencOn the afternoon of November 2, Shi Yuanyuan, chairman of our company, was invited to attend the closed-door meeting of industrial leaders of the 2022 Shenzhen ...01-15 -
Help NK cell therapy - Shenzhen Cell Valley and Enkesai reach a comprehensive strategic cooperationFrom September 26 to 27, 2022, Professor Shi Yuanyuan, Chairman of Shenzhen Cell Valley Biomedicine Co., LTD., Professor Wang Jianxun, Chief scientist of Shenzh...01-15
-
Shenzhen Cell Valley and Lu Daopei Medical Group to carry out in-depth cooperationRecently, Dr. Shi Yuanyuan, Chairman of the Company, met with Ms. Zhao Yi, Chief Operating Officer of Lu Daopei Medical Group, Mr. CAI Peng, General Manager of ...01-15
